Dual targeting nanoparticles for epilepsy therapy.

Area of Science:

• Nanotechnology
• Neuroscience
• Pharmacology

Background:

• Epilepsy affects millions globally, with a significant portion resistant to current antiepileptic drugs.
• The blood-brain barrier (BBB) impedes effective drug delivery to the brain, limiting therapeutic options.

Purpose of the Study:

• To develop a novel nanoparticle system for enhanced drug delivery across the BBB for epilepsy treatment.
• To improve the therapeutic efficacy of lamotrigine in epilepsy by targeting specific brain cells.

Main Methods:

• Fabrication of double-targeting nanoparticles using a microfluidic chip, encapsulating lamotrigine (LTG) in poly(lactic-co-glycolic acid) (PLGA).
• Functionalization of nanoparticles with D-T7 peptide for BBB targeting and Tet1 peptide for neuron targeting.
• In vitro and in vivo evaluation of nanoparticle targeting efficiency, antiepileptic activity, and neuroprotective effects.

Main Results:

• The developed D-T7/Tet1-lipids@PL nanoparticles successfully crossed the blood-brain barrier.
• Nanoparticles demonstrated excellent targeting of neurons.
• Significant antiepileptic and neuroprotective effects were observed in vitro and in vivo.

Conclusions:

• This study presents a promising dual-targeting nanoparticle strategy to overcome BBB limitations in epilepsy therapy.
• The D-T7/Tet1-lipids@PL nanoparticles offer a new approach to enhance the efficacy of existing antiepileptic drugs like lamotrigine.